Inside Biotech: ENA Respiratory secures A$2.98 million to advance INNA-051 asthma study
Biotech firm ENA Respiratory has secured A$2.98 million in funding from Biointelect Venturer to advance its clinical study of INNA-051 for asthma treatment. The company is part of the broader biotech sector focused on developing respiratory therapies.
Why it matters
Securing capital is a critical milestone for biotech startups to move experimental treatments through clinical trials toward market viability.
Jonathan Jackson is an experienced writer and editor. Over the past 20 years, he has worked in print and digital media across several business and finance titles amd is currently the Australian news editor at Proactive Investors covering the latest news for ASX listed companies as well as current financial trends. He was previously managing editor with Business First magazine, Wealth Creator Magazine and StocksDigital. Jonathan has interviewed some of the world's top CEOs and covered...
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.
Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in